Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Atirmociclib | C22H27ClFN5O3 | CID 146219790 - PubChem
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 ...
RCSB PDB - 9D8U: Crystal structure of CDK6 in complex with atirmociclib
Atirmociclib - Pfizer - AdisInsight
Atirmociclib
Atirmociclib (PF-07220060) | Pfizer Oncology Development Website
Atirmociclib | Drug Information, Uses, Side Effects, Chemistry ...
Pfizer’s atirmociclib promising in second-line metastatic breast cancer ...
Pfizer touts atirmociclib success | ApexOnco - Clinical Trials news and ...
Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and ...
Pfizer dials down its atirmociclib ambitions | ApexOnco - Clinical ...
8款以上潜在重磅疗法！辉瑞肿瘤学研发管线聚焦3大治疗模式（附PDF下载）_腾讯新闻
《癌细胞》：更新换代，效果不赖！临床前研究显示，新一代CDK4选择性抑制剂抗肿瘤效果好、毒性小_腾讯新闻
PF-07220060
atirmociclib(PF-07220060)
RCSB PDB - 9CSK: Crystal structure of CDK4 cyclin D1 in complex with ...
Targeting CDK4/6 for Anticancer Therapy
2022年FDA批准的15个小分子：临床用途及其合成 - 脉脉
Eliquis maker Bristol Myers Squibb sues over Medicare plan to cut drug ...
Abstract P5-07-28: The next-generation CDK4-selective inhibitor ...
Inter-Antibody Variability in the Clinical Pharmacokinetics of ...
CDK Inhibitors and FDA: Approved and Orphan
Abemaciclib, a Recent Novel FDA-Approved Small Molecule Inhibiting ...
Spectrum and Degree of CDK Drug Interactions Predicts Clinical ...
Frontiers | Design, synthesis, and anticancer activity of three novel ...
FDA approves first vaccine to protect newborns from RSV | CNN
casdatifan (AB521)
Development of CDK4/6 Inhibitors: A Five Years Update
Slide 11
Synthetic Approaches and Clinical Application of Representative Small ...
Frontiers | Transcription and Translation Inhibitors in Cancer Treatment
Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6 ...
The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in ...
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for ...
Breaking Cancer’s Momentum: CDK4/6 Inhibitors and the Promise of ...
Lab Study Shows Drug Combination Important to Overcome Drug Resistance ...
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved ...
Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in ...
Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the ...
Inhibitors of cyclin-dependent kinases as cancer therapeutics ...
Abemaciclib cancer drug molecule (CDK inhibitor). Skeletal formula ...
Abemaciclib cancer drug molecule cdk inhibitor Vector Image
WO2021030843A1 - Solid-state forms of abemaciclib, their use and ...
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC ...
Virtual Screening for Identification of Dual Inhibitors against CDK4/6 ...
独特的CDK4 / 6抑制剂：abemaciclib的当前和未来治疗策略,Pharmacological Research - X-MOL
Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity ...
WO2024028411A1 - Combination therapy of cdk7 inhibitors with other anti ...
CDK4/6 inhibitors: a brief overview and prospective research directions ...
Atirmociclib: a selective CDK4 inhibitor for breast cancer ...
下一代CDK4/6抑制剂——Atirmociclib有什么特点？
CDK4 selective inhibition improves preclinical anti-tumor efficacy and ...
JMC | 辉瑞高选择性CDK4抑制剂Atirmociclib迈入III期临床，乳腺癌治疗有望升级 - 知乎
Atirmociclib(Atirmociclib) - 药物靶点：CDK4_在研适应症：HR阳性/HER2阴性乳腺癌，转移性乳腺癌，肺腺癌 ...
(Atirmociclib) - 药物靶点：CDK4_在研适应症：HR阳性/HER2阴性乳腺癌，转移性乳腺癌，肺腺癌_专利_临床_研发
(Atirmociclib) - 药物靶点：CDK4_在研适应症：HR阳性/HER2阴性乳腺癌，肺腺癌，晚期恶性实体瘤_专利_临床_研发
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to ...
TargetMol明星分子—奥沙利铂（铂类抗癌药物）
Atirmociclib(Atirmociclib) - 药物靶点：CDK4_在研适应症：HR阳性/HER2阴性乳腺癌，转移性乳腺癌，晚期恶性 ...
首个获批的选择性 RET 抑制剂Selpercatinib — TargetMol
Profile of palbociclib in the treatment of metastatic breast cancer - PMC
Atirmociclib: Uses, Interactions, Mechanism of Action | DrugBank
Overview - by Cancer | Pfizer Oncology Development Website
.png)
